Key Highlights

  • 614.25 is the negative EPS estimate per the screener snapshot for Jaguar Health, Inc. (NASDAQ:JAGX), an unusual figure that is flagged, ahead of third quarter 2026 results due after the market closes on November 13, 2026.
  • 1.225 million is the USD total Revenue for the second quarter of 2026, down 59% from USD 2.979 million a year earlier, while the net loss attributable to common stockholders was USD 12.69 million.
  • 15.68 is the reported second quarter 2026 loss per share, versus 358.94 a year earlier, a sharp change the release does not explain, while the loss from operations narrowed to USD 7.597 million from USD 8.007 million.
  • 6.44 million is the USD market Capitalization per the screener snapshot, a nano-cap level, and the company expects its crofelemer new drug application for MVID to be submitted in the second quarter of 2027.

What Investors Expect From Jaguar Health (NASDAQ:JAGX) on November 13, 2026

Jaguar Health is listed to report third quarter 2026 results after the market closes (AMC) on November 13, 2026. The consensus estimate per the screener snapshot is a loss of USD 614.25 per share, an extreme figure that is not explained and is presented as the snapshot value only. The second quarter loss was USD 15.68 per share. A year earlier, third quarter revenue was USD 3.08 million and the net loss was USD 9.5 million. Market capitalization per the screener snapshot is USD 6.44 million, which carries nano-cap risk.

The Rationale: Last Reported Quarter and Management Outlook for Jaguar Health (NASDAQ:JAGX)

Second quarter 2026 product revenue was USD 1.182 million versus USD 2.936 million, and non-GAAP recurring EBITDA was a loss of USD 8.381 million. Sales and Marketing expense fell to about USD 5 thousand from USD 2.5 million after the sales group was dissolved on January 12, 2026, while G&A was USD 4.7 million and R&D was USD 3.3 million. Loss on Debt extinguishment was USD 3.5 million. The company expects the MVID clinical package to be ready by the end of 2026. No numerical financial guidance was found.

Valuation, Liquidity and Risks for Jaguar Health (NASDAQ:JAGX)

Per the screener snapshot, Market Value is USD 6.44 million. Cash and debt balances were not found in published coverage of the second quarter. The Future Pak and Woodward licensing deal brought USD 16 million upfront plus a USD 3 million buy-back termination payment, both recognized in the first quarter of 2026, and a USD 2 million holdback was reported as collectible. Deferred revenue was USD 468 thousand. Risks include a small revenue base, losses, regulatory timing and nano-cap volatility, and related releases mention a special Stock Dividend and strategic alternatives that were not detailed.

Where Things Stand

Where things stand: Jaguar Health (NASDAQ:JAGX) reports third quarter 2026 results after the market closes on November 13, 2026, with a snapshot EPS estimate of -614.25 that is flagged as unusual and a market value of USD 6.44 million. The second quarter brought revenue of USD 1.225 million, a loss from operations of USD 7.597 million and a pivot toward crofelemer for rare intestinal failure diseases, backed by the Future Pak licensing arrangement. Pediatric MVID data showed parenteral support reduced by up to 48%. Investors will watch cash, the NDA timeline and any capital actions. This article is informational and is not Investment advice.